Guidance for Industry



Similar documents
Guidance for Industry

Guidance for Industry Consumer-Directed Broadcast Advertisements

Guidance for Industry

Guidance for Industry

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

Guidance for Industry. 21 CFR Part 11; Electronic. Records; Electronic Signatures. Time Stamps

Guidance for Industry

Contains Nonbinding Recommendations

Guidance for Industry

Guidance for Industry COMPUTERIZED SYSTEMS USED IN CLINICAL TRIALS

Guidance for Industry. Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products

Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Electronic Copies of Electronic Records

Guidance for Industry

Guidance for Industry

Guidance for Industry and FDA Staff

DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers

Guidance for Industry. 21 CFR Part 11; Electronic Records; Electronic Signatures. Maintenance of Electronic Records

Guidance for Industry

Guidance for Industry

Use of Electronic Health Record Data in Clinical Investigations

InfoCenter Suite and the FDA s 21 CFR part 11 Electronic Records; Electronic Signatures

Guidance for Industry Independent Consultants for Biotechnology Clinical Trial Protocols

Document issued on: December 2, The draft of this document was issued on March 11, Contains Nonbinding Recommendations

FINAL GUIDANCE. For questions on the content of this guidance, contact Advisory Committee Oversight and Management Staff, at

Guidance for Industry ANDA Submissions Amendments and Easily Correctable Deficiencies Under GDUFA

GUIDANCE FOR INDUSTRY

Guidance for Industry Classifying Resubmissions in Response to Action Letters

Guidance for Industry Certification Process for Designated Medical Gases

The Food and Drug Administration's Policy on Declaring Small Amounts of Nutrients and

Medical Device Data Systems, Medical Image Storage Devices, and Medical Image

Self-Assessment of eresearch Compliance with 21 CFR Part 11, Electronic Record; Electronic Signatures

How To Exempt From Reporting And Recordkeeping Requirements For Tv And Computer Monitors With Cathode Ray Tubes

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only. Document issued on: July 2015

February 2006 Procedural

Guidance for Industry

Guidance for Industry

InfinityQS SPC Quality System & FDA s 21 CFR Part 11 Requirements

Implementation of 21CFR11 Features in Micromeritics Software Software ID

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

The Impact of 21 CFR Part 11 on Product Development

21 CFR Part 11 White Paper

Guidance for Industry

Unique Device Identifier System: Frequently Asked Questions, Vol. 1 Guidance for Industry and Food and Drug Administration Staff

Compliance Response Edition 07/2009. SIMATIC WinCC V7.0 Compliance Response Electronic Records / Electronic Signatures. simatic wincc DOKUMENTATION

Guidance for Industry Part 11, Electronic Records; Electronic Signatures Scope and Application

Guidance for Industry

Guidance for Industry

Guidance for Industry and Investigators Safety Reporting Requirements for INDs and BA/BE Studies- Small Entity Compliance Guide

Contains Nonbinding Recommendations

CLOSING OUT CONSULTING REVIEWS FOR STARS SUBMISSIONS

Guidance for Industry

Guidance for Industry

Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day

Guidance for Industry Time and Extent Applications for Nonprescription Drug Products

Guidance for Industry Direct-to-Consumer Television Advertisements FDAAA DTC Television Ad Pre- Dissemination Review Program

Guidance for Industry and FDA Staff Tonometers - Premarket Notification [510(k)] Submissions

21 CFR Part 11 Implementation Spectrum ES

Guidance for Industry

Electronic records and electronic signatures in the regulated environment of the pharmaceutical and medical device industries

Guidance for Industry. Q10 Pharmaceutical Quality System

Guidance for Sponsors, Investigators, and Institutional Review Boards. Questions and Answers on Informed Consent Elements, 21 CFR 50.

U.S. Food and Drug Administration

Determination of Regulatory Review Period for Purposes of Patent Extension;

interpretation of its Hazard Analysis Critical Control Point (I-IACCP) regulations for fish and fishery

A ChemoMetec A/S White Paper September 2013

Guidance for Industry

FDA Title 21 CFR Part 11:Electronic Records; Electronic Signatures; Final Rule (1997)

q-1'08 date ofpublication in the Federal Register].

Guidance for Industry. Required Warnings for Cigarette Packages and Advertisements

IBM Unica emessage Version 8 Release 6 February 13, User's Guide

SAS IT Resource Management 3.2

Determination of Regulatory Review Period for Purposes of Patent Extension; XARELTO

Guidance for Industry Computerized Systems Used in Clinical Investigations

Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors

Declaration of Conformity 21 CFR Part 11 SIMATIC WinCC flexible 2007

Guidance for Industry. IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations

Guidance for Industry Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation

How To Use Sas With A Computer System Knowledge Management (Sas)

Guidance for Industry Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug Inspection

Guidance for Industry

Guidance for Industry

Guidance for Industry

Recommended Warning for Overthe-Counter. Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions

Guidance for Industry Quality Systems Approach to Pharmaceutical CGMP Regulations

Guidance for Industry

PharmaSUG 2016 Paper IB10

How to easily convert clinical data to CDISC SDTM

Guidance for Industry Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification

FDA Assistance to Industry. Marie Falcone FDA ORA CER Small Business Representative

Guidance for Industry Information Program on Clinical Trials for Serious or Life-Threatening Diseases and Conditions

TIBCO Spotfire and S+ Product Family

A simple tool to catalogue statistical outputs developed for submission by linking two in-house systems experience from a submission project

Guidance for Industry

Review and Approve Results in Empower Data, Meta Data and Audit Trails

Statistical Operations: The Other Half of Good Statistical Practice

DRAFT GUIDANCE. This guidance document is being distributed for comment purposes only.

POLICY ISSUES IN E-COMMERCE APPLICATIONS: ELECTRONIC RECORD AND SIGNATURE COMPLIANCE FDA 21 CFR 11 ALPHATRUST PRONTO ENTERPRISE PLATFORM

Transcription:

#197 Guidance for Industry Documenting Statistical Analysis Programs and Data Files This version of the guidance replaces the version made available in May 2010. This document has been revised to update contact information, hyperlinks, and standard disclosures. Submit comments on this guidance at any time. Submit electronic comments on the guidance to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Room 1061, Rockville, MD 20852. All written comments should be identified with the Docket No. FDA-2009-D-0052. For questions regarding this guidance, contact: Virginia Recta, Center for Veterinary Medicine (HFV-160), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 240-402- 0840; e-mail: virginia.recta@fda.hhs.gov. Additional copies of this guidance document may be requested from the Policy and Regulations Staff (HFV-6), Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Place, Rockville, MD 20855, and may be viewed on the Internet at either http://www.fda.gov/animalveterinary/default.htm or http://www.regulations.gov. U.S. Department of Health and Human Services Food and Drug Administration Center for Veterinary Medicine December 2015

TABLE OF CONTENTS I. INTRODUCTION... 3 II. BACKGROUND... 3 III. INTRODUCTORY MATERIAL... 4 A. Study Number/ Drug/ Sponsor Point of Contact for Statistical Issues... 4 B. Directory and Folder Structure... 4 C. Software Employed to Generate, Read, and Analyze Data Files... 4 D. Overview of Data and Analysis Flow... 5 1. Sequence of Changes in Data Files... 5 2. Program Sequence... 5 3. Table and Graph Mappings... 5 IV. DATA FILES AND VARIABLES... 5 A. Transcribed and Modified Data Files... 5 1. Name and Purpose of Each Data File... 5 2. Variables Definitions... 6 B. Modifications of Transcribed Data... 6 V. INSTRUCTIONS FOR RUNNING PROGRAMS... 6 A. How to Set up Pathnames, Libraries, Custom Styles and Formats... 6 B. Required Program Sequence... 6 C. Diversion and Resetting of Standard Output... 6 D. Software Termination Statements in Programs... 6 VI. PROGRAM COMMENTS... 6 VII. RANDOMIZATION... 7 A. Allocation Tables... 7 B. Process Used to Generate Allocation Tables... 7 VIII. LOG AND OUTPUT FILES... 7 2

Guidance for Industry Documenting Statistical Analysis Programs and Data Files 1 This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA office responsible for this guidance as listed on the title page. I. INTRODUCTION This guidance is provided to inform study statisticians of recommendations for documenting statistical analyses and data files submitted to CVM for the evaluation of safety and effectiveness in new animal drug applications. Sections III XIII of this guidance document describe our recommendations. These recommendations are intended to reduce the number of revisions that may be required for CVM to effectively review statistical analyses and to simplify submission preparation by providing a uniform documentation system. Our recommendations are intended to encompass the most complex data submissions to CVM. We understand that not all submissions are of this complexity; you should refer only to those portions of this guidance applicable to your particular submission. In general, FDA s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in Agency guidances means that something is suggested or recommended, but not required. II. BACKGROUND An adequately documented statistical analysis should include submitted data that are readable, describe how the data are processed, and describe the statistical analyses employed to support your conclusions. Our main concern is that you provide the information we need to understand and access your analyses. The complexity of the documentation will depend to a certain extent upon the programming style you employ. For example, if you provide a single program that specifies locations of data libraries, sets file locations for output and log listings, and calls programs in the appropriate logical sequence, your documentation may refer to that single program. If, on the other hand, you employ multiple programs, your documentation should detail which programs specify locations of data libraries and which programs specify file locations for output and log listings. In addition, if you employ multiple programs, your document should detail the 1 This final guidance document was prepared by the Office of New Animal Drug Evaluation in the Center for Veterinary Medicine, FDA. 3

sequence in which the programs need to be called. Similarly, if you provide a single transcribed data file which contains merged data files describing treatment, inclusion data, and dosing data for each animal, you will not need to document how those merges were performed. Your documentation should clearly describe the entire process by which the analysis was generated, from the transcribed data files, which contain data transcribed from case report forms for each individual animal in the study, to the final statistical analyses, which form the basis for your study s conclusions. For example, to analyze an effectiveness study, you may begin with transcribed data files, which record for each animal: (i) acceptance according to study inclusion criteria; (ii) subsequent randomization into treatment; (iii) administration of specified treatment; (iv) retention of eligibility during the study; and (v) treatment success or failure at study conclusion. Before any of the data for that animal can be analyzed, the entire array of data from case report forms should be compiled into one or more modified data files for analysis. To understand the process by which you compiled the data and conducted the statistical analysis, CVM needs to understand the contents of each data file, the computer programs that compile all the data files together into data files for analysis, and the computer programs that calculate necessary statistics on these analysis data files. Except for comments within programs, you should provide your documentation in a separate readme file. III. INTRODUCTORY MATERIAL A. Study Number/ Drug/ Sponsor Point of Contact for Statistical Issues Your documentation should first include the study name and number, the new animal drug being investigated, and the name of a person CVM should contact to discuss any questions about the documentation. B. Directory and Folder Structure You should explain where all directories and folders containing data or programs may be found in your submission and briefly describe the purpose of each directory and folder. C. Software Employed to Generate, Read, and Analyze Data Files You should provide the name and version number of any software we need to generate, read, or analyze your data files. Data files should be provided on media readable on a personal computer. For example we are able to accept data in SAS System XPORT transport format 2 (Version 5 SAS 2 The description of this format is in the public domain, and data can be translated to and from this format to other commonly used formats without the use of programs from SAS Institute or any specific vendor. Information concerning the SAS System XPORT transport format may be currently found on the internet at http://www.sas.com/en_us/industry/government/accessibility/accessibility-compliance.html#fda-submissionsstandards 4

transport format), an open format published by the SAS Institute. If you wish to provide data files or output which can neither be read by the operating system nor read as SAS XPORT transport files, you should contact CVM. D. Overview of Data and Analysis Flow 1. Sequence of Changes in Data Files You should provide a step-by-step overview of modifications in transcribed data files made to generate the final analysis data files including, for example, merges of data files, data exclusions, and data transformations, and name the program used to generate each modification. 2. Program Sequence You should provide a general overview of the program flow used in your submission. Starting with the first program called, you should document all calls to other programs, custom functions, and macros, in sequence, including both interactive calls and calls made within programs. 3. Table and Graph Mappings You should name the program used to generate each analysis, table, and graph provided in your submission. IV. DATA FILES AND VARIABLES The data files directly employed in statistical analyses may have been derived from one or more transcribed data files. You should document all such derived data files external to the programming code. You should include the name and purpose of each derived data file and describe each field (column) in each derived data file, including the field s name, purpose, and, where applicable, labels as well as units of measurement. You should include definitions of codes used for categorical variables and, if categorical variables in data files are not formatted by the programs provided, you should provide instructions for including the formats so that data files can be read. You should explain any alterations of data on individual subjects, e.g., corrections or changes in inclusion status or measured data, and describe any data manipulations used to create the data files such as merges, calculation of derived variables, recoding of categorical variables, and data transformations. A. Transcribed and Modified Data Files 1. Name and Purpose of Each Data File You should describe the purpose of each data file. 5

2. Variables Definitions External documentation for each field in each data file should include the field name, definition, and, where applicable, labels, formats, and units of measurement. B. Modifications of Transcribed Data You should describe, and explain the reason for, any modifications of data on individual subjects, e.g., corrections or changes in inclusion status, changes in data values, calculation of derived variables, recoding of categorical variables, and data transformations. V. INSTRUCTIONS FOR RUNNING PROGRAMS A. How to Set up Pathnames, Libraries, Custom Styles and Formats For each program, you should document all directories and files referenced to access or store data, including directory and file names, locations, and aliases. You should also document the location of programs defining custom styles or formats or, if such styles or formats are predefined, you should provide instructions for their installation. B. Required Program Sequence You should describe the sequence of program calls needed for CVM to run your programs. C. Diversion and Resetting of Standard Output You should name any programs that divert log files and analysis output away from default, e.g., from windows to stored files, and name any programs that divert such listings back to default. When diversion is to stored files, you should specify the name of each file and the directory in which it will be stored. D. Software Termination Statements in Programs You should describe any statements employed in your programs that terminate software sessions, including the program name and where in each program they occur. VI. PROGRAM COMMENTS You should describe the general purpose of the program at the beginning. Within the program, you should include sufficient comments to explain complex sections. 6

VII. RANDOMIZATION A. Allocation Tables You should provide the allocation tables used for any randomization, e.g., experimental units to treatments, order of necropsy. B. Process Used to Generate Allocation Tables You should describe the process used to generate your allocation tables, including any programs used. VIII. LOG AND OUTPUT FILES In your submission, you should provide in stored files all log and output listings generated by your programs. 7